[go: up one dir, main page]

BRPI0414266A - derivados de tiazolopiridina como ligandos receptores da adenosina - Google Patents

derivados de tiazolopiridina como ligandos receptores da adenosina

Info

Publication number
BRPI0414266A
BRPI0414266A BRPI0414266-7A BRPI0414266A BRPI0414266A BR PI0414266 A BRPI0414266 A BR PI0414266A BR PI0414266 A BRPI0414266 A BR PI0414266A BR PI0414266 A BRPI0414266 A BR PI0414266A
Authority
BR
Brazil
Prior art keywords
lower alkyl
disease
heterocyclyl
compounds
substituents selected
Prior art date
Application number
BRPI0414266-7A
Other languages
English (en)
Inventor
Roger David Norcross
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0414266A publication Critical patent/BRPI0414266A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"DERIVADOS DE TIAZOLOPIRIDINA COMO LIGANDOS RECEPTORES DA ADENOSINA". A presente invenção diz respeito aos compostos da fórmula geral (I) em que R¬ 1¬ é morfolin-4-ila, fenila ou tetraidropiran-4-ila; R¬ 2¬ é -(CH~ 2~)~ n~-arila, não substituída ou substituída por um ou mais substituintes, selecionados do grupo consistindo de halogeno, alcóxi inferior, alquila inferior, -(CH~ 2~)~ n~NR<39>R<39><39>, -O(CH~ 2~)~ n~-O-alquila inferior, ou -(CH~ 2~)~ n~-heterociclila, ou é heteroarila, não substituída ou substituída por um ou mais substituintes, selecionados do grupo consistindo de alquila inferior, alcóxi inferior, -(CH~ 2~)~ n~ NR<39>R<39><39>, -(CH~ 2~)~ n~heterociclila, que é opcionalmente substituída por hidróxi ou alcóxi inferior, ou é -(CH~ 2~)~ n~-heterociclila, opcionalmente substituída por um ou mais substituintes selecionados do grupo consistindo de -(CH~ 2~)~ n~-OH, -(CH~ 2~)~ n~-O-alquila inferior ou alquila inferior, ou é -(CH~ 2~)~ n~-cicloalquila, ou é -(CH~ 2~)~ n~-O-alquila inferior, ou é NR<39>R<39><39>, ou é benzo¢1,3!dioxol, 2-metil-1-oxo-2,8-diaza-espiro ¢4,5!decano, 2-oxa-5-aza-biciclo¢2,2,1!heptano ou 1-oxa-8-aza-espiro ¢4,5! decano; R<39>,R<39><39> são independentemente um do outro alquila inferior, -(CH~ 2~)~ n~O-alquila inferior ou cicloalquila, opcionalmente substituída por hidróxi; n é 0, 1 ou 2; e aos sais de adição de ácido farmaceuticamente aceitáveis destes. Estes compostos podem ser utilizados no controle ou prevenção de enfermidades que se baseiam na modulação do sistema de adenosina, tal como doença de Alzheimer, doença de Parkinson, doença de Huntington, neuro-proteção, esquizofrenia, ansiedade, dor, déficit da respiração, depressão, vício de drogas, tais como anfetamina, cocaína, opióides, etanol, nicotina, canabinóides, ou contra asma, respostas alérgicas, hipoxia, isquemia, ataque apoplético e abuso de substâncias. Além disso, os compostos da presente invenção podem ser úteis como sedativos, relaxantes musculares, antipsicóticos, antiepilépticos, anticonvulsivantes e agentes cardioprotetores para os distúrbios tais como doença da artéria coronária e insuficiência cardíaca. As indicações mais preferíveis de acordo com a presente invenção são aquelas que incluem os distúrbios do sistema nervoso central, por exemplo, o tratamento ou prevenção da doença de Alzheimer, certos distúrbios depressivos, vício de drogas, neuroproteção e doença de Parkinson assim como ADHD.
BRPI0414266-7A 2003-09-19 2004-09-11 derivados de tiazolopiridina como ligandos receptores da adenosina BRPI0414266A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03021119 2003-09-19
PCT/EP2004/010179 WO2005028484A1 (en) 2003-09-19 2004-09-11 Thiazolopyridine derivatives as adenosine receptor ligands

Publications (1)

Publication Number Publication Date
BRPI0414266A true BRPI0414266A (pt) 2006-11-07

Family

ID=34306777

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414266-7A BRPI0414266A (pt) 2003-09-19 2004-09-11 derivados de tiazolopiridina como ligandos receptores da adenosina

Country Status (13)

Country Link
US (1) US7273865B2 (pt)
EP (1) EP1670805A1 (pt)
JP (1) JP2007505851A (pt)
KR (1) KR20060058132A (pt)
CN (1) CN1871244A (pt)
AR (1) AR045659A1 (pt)
AU (1) AU2004274154A1 (pt)
BR (1) BRPI0414266A (pt)
CA (1) CA2539314A1 (pt)
MX (1) MXPA06002943A (pt)
RU (1) RU2006112847A (pt)
TW (1) TWI297339B (pt)
WO (1) WO2005028484A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
WO2004056363A2 (en) 2002-12-20 2004-07-08 Niconovum Ab A physically and chemically stable nicotine-containing particulate material
AU2006218404A1 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. N-phenyl benzamide derivatives as sirtuin modulators
US8093401B2 (en) * 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) * 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
CA2618360C (en) * 2005-08-04 2015-06-09 Sirtris Pharmaceuticals, Inc. Benzothiazoles and thiazolopyridines as sirtuin modulators
US20070213311A1 (en) * 2006-03-02 2007-09-13 Yun-Long Li Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
AU2007224584A1 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
US20070293529A1 (en) * 2006-05-01 2007-12-20 Yun-Long Li Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1
CA2651769C (en) * 2006-05-18 2013-12-17 F. Hoffmann-La Roche Ag Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists
FR2913886B1 (fr) 2007-03-22 2012-03-02 Guerbet Sa Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer
CL2008001822A1 (es) * 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
KR20100092000A (ko) * 2007-11-01 2010-08-19 서트리스 파마슈티컬즈, 인코포레이티드 시르투인 조절제로서의 아미드 유도체
AU2008325148A1 (en) * 2007-11-08 2009-05-14 Sirtris Pharmaceuticals, Inc. Solubilized thiazolopyridines
CN102388054B (zh) 2008-12-19 2015-03-04 西特里斯药业公司 噻唑并吡啶沉默调节蛋白调节剂的化合物
CA2929502A1 (en) 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Substituted pyridine derivatives useful as gsk-3 inhibitors
EP3066093B9 (en) 2013-11-06 2018-02-07 Bristol-Myers Squibb Company Gsk-3 inhibitors
WO2015091584A1 (en) * 2013-12-18 2015-06-25 F. Hoffmann-La Roche Ag Thiazolopyridine compounds, compositions and their use as tyk2 kinase inhibitors
CN103720703A (zh) * 2013-12-24 2014-04-16 新乡医学院第一附属医院 腺苷a2a受体特异性阻断剂对延髓呼吸中枢的作用
IT201600070952A1 (it) * 2016-07-07 2018-01-07 Univ Degli Studi Di Ferrara NUOVI TIAZOLO[5,4-d]PIRIMIDIN DERIVATI QUALI AGONISTI INVERSI DEI RECETTORI A2A DELL’ADENOSINA
PT3661941T (pt) * 2017-08-01 2023-03-16 Merck Patent Gmbh Derivados tiazolopiridina como antagonistas do recetor de adenosina
JP7287951B2 (ja) 2017-08-21 2023-06-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング アデノシン受容体アンタゴニストとしてのキノキサリン誘導体
EP3672952B1 (en) 2017-08-21 2022-12-14 Merck Patent GmbH Benzimidazole derivatives as adenosine receptor antagonists
WO2020083878A1 (en) 2018-10-25 2020-04-30 Merck Patent Gmbh 5-azaindazole derivatives as adenosine receptor antagonists
US12194051B2 (en) 2018-10-25 2025-01-14 Merck Patent Gmbh 5-azaindazole derivatives as adenosine receptor antagonists
CN111205244B (zh) * 2018-11-22 2023-08-18 上海科技大学 噻唑并环类化合物、其制备方法、中间体和应用
AR117844A1 (es) 2019-01-22 2021-09-01 Merck Patent Gmbh Derivados de tiazolopiridina como antagonistas del receptor de adenosina

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2299504T3 (es) * 2000-06-21 2008-06-01 F. Hoffmann-La Roche Ag Derivados de benzotiazol para el tratamiento de la enfermedad de alzheimer y de la enfermedad de parkinson.
US6620811B2 (en) * 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
US6599901B1 (en) * 2001-11-19 2003-07-29 Hoffman-La Roche Inc. Pyridone substituted benzothiazole derivatives
US6624163B2 (en) * 2001-11-29 2003-09-23 Hoffman-La Roche Inc. Benzothiazole derivatives
US6727247B2 (en) * 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives
US6713499B2 (en) * 2001-12-12 2004-03-30 Hoffman-La Roche Inc. 7-Amino-benzothiazole derivatives
US6734179B2 (en) * 2001-12-12 2004-05-11 Hoffmann-La Roche Inc. Benzothiazoles
AU2002358597C1 (en) * 2001-12-12 2008-09-18 F. Hoffmann-La Roche Ag Benzothiophenes as adenosine receptor modulators

Also Published As

Publication number Publication date
MXPA06002943A (es) 2006-05-31
WO2005028484A1 (en) 2005-03-31
JP2007505851A (ja) 2007-03-15
KR20060058132A (ko) 2006-05-29
TW200526670A (en) 2005-08-16
RU2006112847A (ru) 2007-11-10
AR045659A1 (es) 2005-11-02
US20050065151A1 (en) 2005-03-24
CA2539314A1 (en) 2005-03-31
AU2004274154A1 (en) 2005-03-31
US7273865B2 (en) 2007-09-25
TWI297339B (en) 2008-06-01
CN1871244A (zh) 2006-11-29
EP1670805A1 (en) 2006-06-21

Similar Documents

Publication Publication Date Title
BRPI0414266A (pt) derivados de tiazolopiridina como ligandos receptores da adenosina
BRPI0407543A (pt) derivados de piperidina-benzenossulfonamida
BRPI0415746A (pt) derivados de amida
BR0309167A (pt) Composto, processo para a produção de um composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito afetado por uma condição patológica ou doença e produto de combinação
SE0104334D0 (sv) Therapeutic agents
BRPI0418102A (pt) derivados de quinolina
BR0214221A (pt) Derivados de benzotiazol como ligantes de receptores de adenosina
BRPI0512535A (pt) compostos de piperidinas n-substituìdas, suas composições e métodos de modulações
BR0209271A (pt) Composto, uso de um composto composição farmacêutica, formulação em aerossol farmacêutica, método para o tratamento de um paciente humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para a preparação de um composto
CN102046625A (zh) 桥连杂环化合物及其使用方法
BRPI0407253A (pt) Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos
BRPI0516219A (pt) composto de carboestirila
BRPI0408591A (pt) derivados de 6,7,8,9-tetrahidropirimido[1,2-a] pirimidin-4-ona 8-substituìda
HRP20090143T3 (en) N-oxides as prodrugs of piperazine&amp;piperidine derivatives
BRPI0408605A (pt) derivados de 8-perfluoralquil-6,7,8,9-tetrahidropirimido[1,2-a]piri midin-4-ona substituìdos
NO20082679L (no) Sammensetning og fremgangsmate for a behandle CNS lidelser
BR0311840A (pt) Composto, formulação farmacêutica, método para tratar ou evitar resistência à insulina, uso de um composto, e, processo para prepará-lo
WO2008009741A1 (en) Novel chromene and thiochromene carboxamide derivatives, methods for preparing same and therapeutic applications of same
UA87142C2 (en) 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide
BRPI0411285A (pt) composto, processo para preparar um composto formulação farmacêutica, uso de um composto, e, método de prevenção ou tratamento de distúrbios
BR0311315A (pt) Sulfonas aromáticas e sua utilização médica
BRPI0408248A (pt) derivados azabicìclicos de piridiloximetila e de benzisoxazol
BRPI0517740A (pt) compostos n-sulfonilaminobenzil-2fenóxi acetamida substituìda
BRPI0409302A (pt) derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos
BRPI0512680A (pt) derivados de oxopiperidina, sua preparação e sua aplicação em terapêutica

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.